Cargando…

Preclinical and Clinical Development of Noncoding RNA Therapeutics for Cardiovascular Disease

RNA modulation has become a promising therapeutic approach for the treatment of several types of disease. The emerging field of noncoding RNA-based therapies has now come to the attention of cardiovascular research, in which it could provide valuable advancements in comparison to current pharmacothe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Cheng-Kai, Kafert-Kasting, Sabine, Thum, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7043728/ https://www.ncbi.nlm.nih.gov/pubmed/32105576 http://dx.doi.org/10.1161/CIRCRESAHA.119.315856

Ejemplares similares

Therapeutic and Diagnostic Translation of Extracellular Vesicles in Cardiovascular Diseases: Roadmap to the Clinic
por: Sahoo, Susmita, et al.
Publicado: (2021)

MicroRNA therapeutics in cardiovascular medicine
por: Thum, Thomas
Publicado: (2012)

Autophagy in cardiovascular diseases: role of noncoding RNAs
por: Gao, Jinning, et al.
Publicado: (2020)

Alternative strategies in cardiac preclinical research and new clinical trial formats
por: Kreutzer, Fabian Philipp, et al.
Publicado: (2021)

Noncoding RNAs as Key Regulators for Cardiac Development and Cardiovascular Diseases
por: Kawaguchi, Satoshi, et al.
Publicado: (2023)

Expedition to the missing link: Long noncoding RNAs in cardiovascular diseases
por: Yeh, Chih-Fan, et al.
Publicado: (2020)

The Emerging Role of Noncoding RNA Regulation of the Ferroptosis in Cardiovascular Diseases
por: Zhang, Jing, et al.
Publicado: (2022)

The noncoding-RNA landscape in cardiovascular health and disease
por: Di Mauro, Vittoria, et al.
Publicado: (2018)

Noncoding RNA in age-related cardiovascular diseases
por: Greco, Simona, et al.
Publicado: (2015)

Novel approaches in cancer treatment: preclinical and clinical development of small non-coding RNA therapeutics
por: Cuciniello, Rossana, et al.
Publicado: (2021)

Epigenetic modifications in cardiovascular disease
por: Lorenzen, Johan M., et al.
Publicado: (2012)

Mechanisms of long noncoding RNA function in development and disease
por: Schmitz, Sandra U., et al.
Publicado: (2016)

Development of Long Noncoding RNA-Based Strategies to Modulate Tissue Vascularization
por: Fiedler, Jan, et al.
Publicado: (2015)

Long Noncoding Competing Endogenous RNA Networks in Age-Associated Cardiovascular Diseases
por: Greco, Simona, et al.
Publicado: (2019)

Role of Noncoding RNA in Development of Nonalcoholic Fatty Liver Disease
por: Huang, Ruixian, et al.
Publicado: (2019)

Therapeutic potential of extracellular vesicle‐associated long noncoding RNA
por: Born, Louis J., et al.
Publicado: (2020)

Select Macrophage Noncoding RNAs of Interest in Cardiovascular Disease
por: Enchill, Zenaida, et al.
Publicado: (2020)

Preclinical Development of siRNA Therapeutics for AL Amyloidosis
por: Hovey, Beth M., et al.
Publicado: (2011)

Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings
por: Germovsek, Eva, et al.
Publicado: (2021)

Regulation of pyroptosis in cardiovascular pathologies: Role of noncoding RNAs
por: Gao, Jinning, et al.
Publicado: (2021)

Facts and updates about cardiovascular non‐coding RNAs in heart failure
por: Thum, Thomas
Publicado: (2015)

miR-21, Mediator, and Potential Therapeutic Target in the Cardiorenal Syndrome
por: Huang, Cheng-Kai, et al.
Publicado: (2020)

The Effect of Testosterone on Cardiovascular Disease and Cardiovascular Risk Factors in Men: A Review of Clinical and Preclinical Data
por: Kaur, Hargun, et al.
Publicado: (2021)

Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns
por: Cunningham, Orla, et al.
Publicado: (2021)

Role of MicroRNA in Inflammatory Bowel Disease: Clinical Evidence and the Development of Preclinical Animal Models
por: Suri, Kanika, et al.
Publicado: (2021)

Noncoding-RNA-Based Therapeutics with an Emphasis on Prostatic Carcinoma—Progress and Challenges
por: Nava, Victor E., et al.
Publicado: (2022)

Developing preclinical models of neuroblastoma: driving therapeutic testing
por: Ornell, Kimberly J., et al.
Publicado: (2019)

Noncoding RNAs implication in cardiovascular diseases in the COVID-19 era
por: Greco, S., et al.
Publicado: (2020)

Are Parkinson’s Disease Patients the Ideal Preclinical Population for Alzheimer’s Disease Therapeutics?
por: Tropea, Thomas F., et al.
Publicado: (2021)

Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics
por: Huang, Yuanyu
Publicado: (2017)

The role of long noncoding RNA Nron in atherosclerosis development and plaque stability
por: Du, Meng, et al.
Publicado: (2022)

Long noncoding RNA in cardiac aging and disease
por: Lozano-Vidal, Noelia, et al.
Publicado: (2019)

Extracellular Vesicle-Based Therapeutics: Preclinical and Clinical Investigations
por: Klyachko, Natalia L., et al.
Publicado: (2020)

Long noncoding RNAs in development and cancer: potential biomarkers and therapeutic targets
por: Fatima, Roshan, et al.
Publicado: (2015)

Harnessing noncoding RNA‐based macrophage polarization: Emerging therapeutic opportunities for fibrosis
por: Zhou, Dexi, et al.
Publicado: (2020)

Long noncoding RNAs in cardiovascular disease
por: Kohlmaier, Alexander, et al.
Publicado: (2023)

Noncoding RNA therapeutics — challenges and potential solutions
por: Winkle, Melanie, et al.
Publicado: (2021)

Noncoding RNA therapeutics for substance use disorder
por: Seyednejad, Seyed Afshin, et al.
Publicado: (2022)

Reactive Oxygen Species Related Noncoding RNAs as Regulators of Cardiovascular Diseases
por: Dong, Yanhan, et al.
Publicado: (2019)

Ramucirumab: preclinical research and clinical development
por: Aprile, Giuseppe, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_vifhtiuan2bc99p52k0b8g1ov5